QP 40 - Personalized Therapy and Special populations in Head and Neck Cancer

Presentations

• 09:15am - 09:20am ET

  Introductions

  Speaker: Lachlan McDowell, PhD, MBBS, FRANZCR - Princess Alexandra Hospital, Woolloongabba
• 09:20am - 09:25am ET

  Hypo-Slow Radiotherapy Combined with Capecitabine in Very Elderly Patients (=78 Years) with Locally Advanced Head and Neck Cancer: A Prospective Exploratory Study

  Speaker: Yue Zhao, MD, PhD - China, Chengdu
• 09:25am - 09:30am ET

  Split-Course Hypofractionated Radiotherapy in Elderly Patients with Head and Neck Squamous Cell Carcinoma: A Single-Center Prospective Phase II study

  Speaker: Jia-Xuan Yang, MS - National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy, Beijing
• 09:30am - 09:35am ET

  Somatic Genetic Variants as Predictors for Radiation-Induced Short and Long-Term Toxicity in Head and Neck Cancers

  Speaker: Austin Thompson, MD - University of Maryland Medical Center, Baltimore
• 09:35am - 09:40am ET

  Genetic Signatures Predicting Toxicity and Overall Survival in Head and Neck Squamous Cell Carcinoma (HNSCC) Patients in RTOG 0522 Treated with Radiation and Cisplatin

  Speaker: Joanne Weidhaas, MD, PhD - UCLA Radiation Oncology, Los Angeles
• 09:40am - 09:45am ET

  Stereotactic Ablative Radiotherapy (SABR) for Early Stage Glottic Cancer: A Multi-Institutional Pooled Analysis of Long-Term Efficacy, Toxicity and Voice Outcomes

  Speaker: Sympascho Young, MD, BS - UT Southwestern Medical Center, Dallas
• 09:45am - 09:50am ET

  Prospective Evaluation of Daily Online Adaptive Radiotherapy with 1mm PTV Margins in High Risk HPV Negative Head and Neck Cancer

  Speaker: Harjot Bajwa, MD - American Oncology Institute, Hyderabad
• 09:50am - 10:10am ET

  Questions & Answers

  Speaker: Ryan Morse, MD - University of Kansas Medical Center, Kansas City
• 10:10am - 10:15am ET

  Closing

  Speaker: Lachlan McDowell, PhD, MBBS, FRANZCR - Princess Alexandra Hospital, Woolloongabba